Mark - Asabys Partners

Internal

September 15, 2022

Asabys launches a new €200m fund to invest in biotech & healthtech

READ THIS NEWS IN SPANISH The fund’s first closing is expected by the end of…

Mark

Portfolio

September 13, 2022

Agomab Therapeutics Selected as One of Fierce Biotech’s “Fierce 15” Companies of 2022

Agomab Therapeutics NV (‘Agomab’) today announced that Fierce Biotech has named the company as one…

Mark

Portfolio

July 13, 2022

Agomab Raises Additional $40.5 Million Through Series B Extension Bringing Total Amount to $114M

READ THIS NEWS IN SPANISH ● Extension led by Pfizer with participation from new investors…

Mark

Portfolio

June 28, 2022

Amelia Virtual Care welcomes new investors and strengthens its management team

READ THIS NEWS IN SPANISHAmelia Virtual Care, mental health technology company with offices in Barcelona…

Mark

Portfolio

May 13, 2022

Digital digestive health therapeutic Cara Care lands $7M investment, appoints James “Jim” Mapes CEO

READ THIS NEWS IN SPANISHCara Care announced a $7M equity financing round today led by…

Mark

Portfolio

May 10, 2022

Nuage Therapeutics appoints biotech entrepreneur and executive Judit Anido as CEO

READ THIS NEWS IN SPANISH Judit Anido joins Nuage Therapeutics as co-founder and CEO and…

Mark

Portfolio

May 5, 2022

Digital Therapeutics Leader Sidekick Raises $55M Series B To Drive Further Growth

READ THIS NEWS IN SPANISH The closing of the company’s B Series follows an oversubscribed…

Mark

Internal

February 18, 2022

Asabys Partners da entrada al FEI y eleva su primer fondo a 117 millones

https://www.expansion.com/catalunya/2022/02/18/620ea6ed468aeb34408b45d3.html Related news BACK TO NEWS

Mark

Portfolio

February 16, 2022

SpliceBio Raises EUR 50M in Oversubscribed Series A financing to Advance Protein Splicing Platform and Expand Gene Therapy Pipeline

READ THIS NEWS IN SPANISH Financing co-led by UCB Ventures and Ysios Capital with participation…

Mark

Portfolio

December 15, 2021

Agomab Therapeutics Completes Acquisition of Origo Biopharma

Agomab Therapeutics NV (‘Agomab’) announced today the closing of the Origo Biopharma acquisition. The transaction,…

Mark

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duration	Description
cookielawinfo-checbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Functional

Performance

Analytics

Others